Medigus' MUSE(TM) Procedure for the Treatment of GERD Now

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Medigus' MUSE(TM) Procedure for the Treatment of GERD Now Available in Germany

OMER, Israel, May 6, 2015 (GLOBE NEWSWIRE) -- Medigus Ltd. (TASE: MDGS ), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, announced today the third MUSE™ procedure in a three-month period was completed in Germany. Renowned gastroenterologist, Professor Doctor Karel Caca at the Clinic for Internal Medicine, Gastroenterology, Haemato-Oncology, Diabetes and Infectious Disease, recently adopted this new technology to offer his patients the most innovative care. The Medigus Ultrasonic Surgical Endostapler, or MUSE, is an incisionless procedure for the treatment of gastroesophageal reflux disease (GERD).

"By offering the MUSE procedure, my patients now have a less invasive option for the long-term treatment of GERD," said Dr. Caca. "The reduced recovery time and reported improvement in symptoms makes it a favorable treatment option."

Medigus has merged recent technological breakthroughs into a single platform with MUSE. The device is fully integrated with leading microvisual, ultrasonic and stapling technology, and therefore allows a single physician or surgeon to perform fundoplication (stapling of the upper part of the stomach, or fundus, to the lower esophageal sphincter), thereby offering a long-term, potentially permanent solution for GERD.

"We're happy to announce that MUSE is now available in Germany and pleased to be working with Dr. Caca," said Chris Rowland, CEO of Medigus. "MUSE is not only a revolutionary new interventional therapy option that is less-invasive for patients, it may also be a more cost-effective option since shorter hospital stays are expected."

Researchers estimate that about 30% of adults in Germany suffer from GERD, and one in ten suffers persistent symptoms several times a week i . MUSE has the potential to improve GERD-related quality of life for many of them by addressing the root cause of the disorder, not just offering symptom relief, which many drug therapies do. 

Medigus' MUSE is FDA cleared and CE marked for the treatment of GERD, and is currently being introduced in key markets across Europe and the U.S. Plans are also in development for distribution in Asia in the next few years. 

About GERD

Gastroesophageal reflux disease (GERD) occurs when the lower esophageal sphincter spontaneously opens or does not properly close after use, thereby allowing for stomach contents to rise into the esophagus, causing heartburn, irritation and potentially other discomforts. It affects approximately 24M Americans each year; 14.5M adults experience GERD symptoms at least twice a week, and 2.4M adults experience severe symptoms. While some patients can attain symptom relief through the use of proton pump inhibiters, or PPIs, (acid reducing medications), there is, however, growing concern around the prolonged chronic use of PPIs, including increased risk of bone fracture, infectious complications, and interference with anti-platelet medication and the adsorption of essential vitamins and minerals. A persistent state of untreatable GERD could potentially lead to Barrett's esophagus, a precancerous state which can lead to esophageal cancer. Patients who suffer from daily GERD are more likely to develop esophageal cancer.

About MUSE

The MUSE system is a leading technology in Natural Orifice Endoscopic Surgery procedures. The single operator system performs anterior partial fundoplication with standard surgical staples in a less invasive way, compared to other surgical procedures. Its intuitive endosurgical platform consists of a single use flexible surgical endostapler, equipped with a proprietary miniature camera, an ultrasonic sight and a range finder. The endostapler, which resembles an endoscope, is designed to be operated by a single user, includes a handle with controls, an 80cm flexible shaft, a 5cm rigid section holding a cartridge with 5 standard 4.8mm titanium surgical staples, a ratchet controlled one-way articulating section, and a distal tip. The MUSE system is FDA cleared and CE marked.

About Medigus

Medigus is a medical device company specializing in developing minimally invasive endosurgical tools and highly innovative imaging solutions. Medigus is a pioneer developer of a unique proprietary endoscopic device, the MUSE™ system, to treat gastroesophageal reflux disease (GERD), one of the most common chronic diseases in the western world. As an expert in micro-endoscopic devices, Medigus has developed a range of micro CMOS (complementary metal-oxide semiconductor) and CCD (charge-coupled device) video cameras, including micro ScoutCam™ 1.2, which to the best of the company's knowledge, is the smallest in the world. These innovative cameras are suitable for both medical and industrial applications. The MUSE system incorporates Medigus' revolutionary micro ScoutCam technology. Based on its proprietary technologies, Medigus designs and manufactures endoscopy and micro camera systems for partner companies, including major players in the medical and industrial fields. The company is committed to providing integrated solutions to meet all of its customer's imaging needs. Medigus is traded on the TASE (Tel-Aviv Stock Exchange). To learn more about the company's advanced technology, please visit www.medigus.com or www.microscoutcam.com .

Cautionary Statement Regarding Forward-Looking Statements

This press release may contain statements that are  "Forward-Looking Statements," which are based upon the current estimates, assumptions and expectations of the company's management and its knowledge of the relevant market. The company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.  By their nature, Forward-Looking Statements involve uncertainties which may cause future results of the company's activity to differ significantly from the content and implications of such statements. Among the factors which may cause the actual results to differ from the Forward-Looking Statements are changes in the target market and the introduction of competitive products, regulatory, legislative and policy changes, and clinical results. Forward-Looking Statements are pertinent only as of the date on which they are made, and the company undertakes no obligation to update or revise any Forward-Looking Statements, whether as a result of new information, future developments or otherwise. Neither the company nor its shareholders, officers and employees, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of company securities. Nothing in this press release should be deemed to be medical or other advice of any kind.

i Koop, H., et al. (2005). Z Gastroenterol. Gastroosophageale Refluxkrankheit - Ergebnisse einer evidenzbarsierten Konsensuskonferenz der Deutschen Gesellschaft fur Verdauungs- und Stoffwechselkrankheiten . New York. © Georg Thieme Verlag KG Stuttgart - New York.

Press release (PDF): http://hugin.info/157792/R/1919097/687025.pdf

MEDIA CONTACT: Chantal Beaudry/ Carrie Yamond Lazar Partners Ltd. 212-867-1762 INVESTOR RELATIONS: Miri Segal-Scharia Hayden/ MS-IR LLC 917-607-8654

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AMP Tests Debt Market With €1.25 Billion Green Notes

Updated Category News Views 101

Refinancing season has arrived early at Ardagh Metal Packaging, and it is carrying a hefty €1.25 billion price tag. AMP has launched senior secured floating-rate green notes, with proceeds intended to retire two batches of secured debt due in 2028 and leave additional cash on the balance sheet for general corporate purposes, including capital expenditure. This is not...

Continue Reading
Hanon's BMW Thermal Win Matters Beyond the Trophy Case Today

Updated Category News Views 96

A 16-Kilogram Box Just Grabbed the Auto Supply Chain’s Attention Hanon Systems did not win these two 2026 PACE honors by polishing up some old hose-and-valve package. Its Highly Integrated Cooling Entity, or HICE, is aimed right at a stubborn electric-vehicle problem: keeping a vehicle’s thermal systems controlled without turning the architecture into a sprawling,...

Continue Reading
Clarivate's 2026 Research List Carries a Trust Test

Updated Category News Views 183

Seven thousand ninety awards can look like a victory lap until you remember how easily raw citation counts can be gamed. Clarivate’s 2026 Highly Cited Researchers list is more interesting for its insistence on screening than for the familiar names at the top. In a research world where publication volume, self-citation and paper mills have made plenty of people...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 54

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
24X Options Filing Puts Earnings Bets Before the SEC

Updated Category News Views 49

An earnings release already turns the market into a bar fight; 24X wants to put part of that fight inside a regulated binary-options contract. The Stamford-based exchange has filed a proposed rule change with the SEC for 24X Options, a facility that would offer a conventional options market alongside contracts tied to company performance targets. It is an interesting...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 85

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 156

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Stitch AI Targets Banking’s Hardest Automation Gap

Updated Category News Views 25

The flashy chatbot stuff is cheap; banking permission to act is not. That is why Stitch AI’s launch deserves more attention than another vendor slapping “agentic” on a slide deck and calling it transformation. Banks do not need a machine to summarize a policy document while everyone applauds the demo. They need technology that can touch real workflows without...

Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability

Updated Category News Views 217

A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...

Continue Reading
A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 131

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading

Top 5 Most Recently Viewed Articles

Voltalia Partners with Retail Giants for EV Charging Stations

Updated Category News Views 165

Innovative Partnership to Enhance Electric Vehicle Charging Voltalia, a prominent name in the renewable energy sector, is making significant strides by collaborating with Auchan, DECATHLON, and Leroy Merlin. This partnership aims to deploy electric vehicle (EV) charging stations across more than 350 parking lots in France, marking a crucial step towards fostering...

Continue Reading
Khanh Phuong Morrow's Strategic Insider Move at Lantheus Holdings

Updated Category News Views 211

Khanh Phuong Morrow's Strategic Insider Decision at Lantheus Holdings In a recent filing, it was disclosed that Khanh Phuong Morrow, a Board Member at Lantheus Holdings (NASDAQ: LNTH), exercised stock options leading to a transaction valued at $0. This decision sheds light on the ongoing activities within the company and showcases the actions of key insiders....

Continue Reading
Investors Urged to Stay Informed on Organon & Co. Class Action

Updated Category News Views 170

Class Action Lawsuit Against Organon & Co. Pomerantz LLP has announced the initiation of a class action lawsuit against Organon & Co. This lawsuit primarily targets investors who have suffered losses relating to their investment in Organon (NYSE: OGN). With the launch of this lawsuit, it is essential for affected investors to understand their rights and options available...

Continue Reading
Sionna Therapeutics Faces Legal Scrutiny Amid Stock Plunge

Updated Category News Views 90

Stock Drop Sparks Legal Action August 10, 2026, wasn't exactly a banner day for Sionna Therapeutics' investors. We're talking about watching a stock nosedive by a jaw-dropping 92%, which is the kind of number that'd knock your socks off under normal circumstances. The catalyst? Some dismal results from the company's Phase 2a proof-of-concept study of SION-719 aimed at...

Continue Reading
Toll Brothers Unveils Stunning New Homes in Chapel Oaks

Updated Category News Views 221

Exciting New Model Homes at Chapel Oaks Community CHAPEL HILL, N.C. – Toll Brothers, Inc. (NYSE: TOL), a prominent name in luxury home construction, has recently announced the opening of their latest model home at the Chapel Oaks community. This new community marks a significant addition to their portfolio in the Raleigh area, providing prospective homeowners with...

Continue Reading